R
Raffaella Origa
Researcher at University of Cagliari
Publications - 98
Citations - 3993
Raffaella Origa is an academic researcher from University of Cagliari. The author has contributed to research in topics: Thalassemia & Deferasirox. The author has an hindex of 25, co-authored 85 publications receiving 3406 citations.
Papers
More filters
Journal ArticleDOI
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia.
Raffaella Origa,Federica Tatti,Antonietta Zappu,Giovan Battista Leoni,Carlo Dessì,Paolo Moi,Maddalena Morittu,Valeria Orecchia,Anna Rita Denotti,Maria Paola Pilia,Franco Anni,Maria Perra,Maria Rosaria Casini,Susanna Barella +13 more
TL;DR: This dissertation aims to provide a history of Hematology/Medical Oncology at the cellular level and investigates the role of “blank-label” chemotherapy in the development of certain types of cancer.
Journal ArticleDOI
Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis
Raffaella Origa,Antonio Piga,Immacolata Tartaglione,Giuseppina Della Corte,Ali El-Ali,Jackie Han,Chiara Castiglioni,Gian Luca Forni +7 more
TL;DR: This retrospective study assessed long-term renal safety of deferasirox in Italian pts with transfusional hemosiderosis who participated in the defer asirox registration studies and continued treatment for up to 10 or more yrs, and found mean SCr and UPCR values were within normal limits and stable over time during the retrospective period.
Journal ArticleDOI
Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS)
Yasser Wali,Tamer Hassan,Pimlak Charoenkwan,Sara Trompeter,Immacolata Tartaglione,Raffaella Origa,Maria Rita Gamberini,Vip Viprakasit,Miguel A. Izquierdo,Socrates Opio,Tania Roy,A. M. Taher +11 more
TL;DR: Treatment adherence is crucial for optimizing long-term iron chelation therapy (ICT) in this patient, which depends on the mode of administration, frequency of dosing, palatability, and the adverse event (AE) profile of ICT.
Journal ArticleDOI
Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies
Maddalena Casale,Marina Baldini,P. Del Monte,Antonia Gigante,Anna Grandone,Raffaella Origa,Maurizio Poggi,Franco Gadda,Rosalba Lai,Monia Marchetti,Gian Luca Forni +10 more
TL;DR: Good Practice Recommendations are the final outcome of translational research and allow one to transfer to the daily clinical practice of endocrine complications in haemoglobinopathies.
Journal ArticleDOI
Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
Filomena Longo,Irene Motta,Valeria Pinto,Andrea Piolatto,Paolo Ricchi,Immacolata Tartaglione,Raffaella Origa +6 more
TL;DR: In this article , the authors developed a set of questions for the practical management of luspatercept in the treatment of beta-thalassemia, which was developed as a consensus by experts from the Italian Society of Thalassemia and Hemoglobinopathies.